

Press Release

September 08, 2016

MagForce AG to present its NanoTherm™ therapy for the treatment of brain tumors at 36th ESSO Congress in Poland

Berlin, Germany and Nevada, USA, September 8, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its attendance at 36th ESSO Congress, held by the European Society of Surgical Oncology from September 14-16, 2016, in Krakow, Poland.

MagForce will be presenting its NanoTherm™ therapy for the treatment of glioblastoma and other brain tumors at booth no. 3.

“Every year more than 152 thousand Poles are diagnosed with cancer and over 95 thousand die each year from their disease. Although therapeutic improvements were achieved in the recent years there is still a high medical need for effective treatment options to help patients suffering from cancer disease. Developing and implementing new therapeutic approaches and making them available to patients all over Europe is of utmost importance. We are committed to support patients from Poland to gain access to those valuable approaches such as NanoTherm™ therapy for the treatment of brain tumors. We are therefore pleased to see that thoughtleaders as well as innovative companies in the field of oncology are meeting at the 36th ESSO Congress in Poland.” **said Bartosz Polinski, CEO of Alivia – Young People Oncology Foundation.**

About ESSO Congress

ESSO's (European Society of Surgical Oncology) mission is to support its members in advancing the science and practice of surgical oncology for the benefit of cancer patients through a range of activities including education, research and leadership in multidisciplinary care.

The 36th ESSO Congress in partnership with the Polish Society of Surgical Oncology focuses on bridging the disparity between minimum standards of care across Europe, the overarching theme of the Congress is 'Optimising European Cancer Surgery'.

ESSO 36 is building on the success of previous congresses, lauded for top-quality scientific programmes and exceptional speakers, by providing delegates with unique educational opportunities and a platform to interact and establish new collaborations and engage with key opinion leaders. The Congress will provide insight into state-of-the-art technology and the latest healthcare services within the field of surgical oncology. Key issues in surgical oncology will be discussed over the three days through range of interactive sessions to highlight the significance of a multidisciplinary approach for management of cancer patient care.

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#)

For meeting arrangements or any further questions, please contact us at:

Patient Advocacy**Dr. Katarzyna Zarychta**

+49 30 95 477 95-66

kzarychta@magforce.com**Media & Investors****Barbara von Frankenberg**

+49 30 30 83 80-77

bfrankenberg@magforce.com**Disclaimer**

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Press ReleaseMagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768